FDA approves the first gene therapy for Pediatric patients with Duchene muscular dystrophy

1. FDA approves Elevidys, the first gene therapy for Duchenne muscular dystrophy.
2. Elevidys delivers micro-dystrophin protein, addressing the root cause of the disease.
3. Clinical trials show increased expression of Elevidys micro-dystrophin in treated patients.

The U.S. Food and Drug Administration has approved Elevidys, the first gene therapy for treating Duchenne muscular dystrophy in pediatric patients aged between 4 and 5. Individuals with Duchenne muscular dystrophy have a gene mutation that results in the absence of dystrophin, a protein that helps keep muscles intact. As a result, these individuals experience trouble walking, fatigue, heart problems, and learning disabilities. Current treatments can only address symptoms, including corticosteroid medications and exercise programs. Treatments like antisense oligonucleotides also have their disadvantages. Therefore, Elevidys brings new hope to patients with Duchenne muscular dystrophy.

The treatment involves delivering a gene into patients, which produces Elevidys micro-dystrophin, a protein with a lower molecular weight compared to natural dystrophin in skeletal muscles. It is administered as a single intravenous dose.

The FDA's accelerated approval of Elevidys is primarily based on results obtained from two clinical trials named SRP-9001-102 and SRP-9001-103. In one study, which was conducted in two parts, Duchenne muscular dystrophy patients aged between 4 and 5 were selected and treated with either Elevidys or a placebo. They were followed for 48 weeks. Then, in part 2, patients who received Elevidys in part 1 were treated with a placebo, and vice versa, and followed for another 48 weeks. Data from the clinical trials show an increase in Elevidys micro-dystrophin expression in patients treated with Elevidys.

Elevidys has not yet been assessed for its clinical benefits, such as motor function. Ongoing clinical trials named EMBARK are being conducted to evaluate the clinical benefits of Elevidys. Once the FDA reviews the results, the Elevidys treatment may be revised or withdrawn. Sarepta Therapeutics has also announced that they will file for a BLA supplement if the EMBARK trial results positively.

This innovative treatment addresses the root cause of the disease by delivering a gene that produces Elevidys micro-dystrophin, a protein crucial for muscle integrity. While further evaluation of its clinical benefits is ongoing, the initial results from clinical trials show promise, with increased expression of Elevidys micro-dystrophin observed in treated patients. With the approval of Elevidys, there is renewed hope for patients with Duchenne muscular dystrophy, offering the potential to improve their quality of life and alter the course of this degenerative disease.

References:

Contributed by: Sarath Kumar

#Biopatrika #SciFocus #GeneTherapy #MuscularDystrophy #PediatricPatients #MedicalBreakthrough #Hope #Elevidys #ScienceNews #FDA #FDAApproval??????

Follow?Virender Singh?and?Biopatrika?on LinkedIn.?

?? Stay connected with the latest news, articles, and career.